New products set to push RSV market to $5.39B by 2028
New research indicates that the respiratory syncytial virus (RSV) market is expected to grow from $418.6 million in 2018 to $5.39 billion by 2028 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) at a compound annual growth rate (CAGR) of 29.1%.
According to data and analytics company GlobalData’s latest report: ‘ Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028’ the main driver of growth will be the launch of new products to prevent medically-significant RSV infections, including vaccines for adult and pediatric patients, as well as single-dose prophylactic monoclonal antibodies (MAbs).
Paul Jeng, senior pharma analyst at GlobalData, noted that Synagis [palivizumab] is currently the only licensed product in the 7MM for prevention of RSV infections in young children, but its high price and restrictive label have narrowed its clinical applications to only the highest-risk infants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze